Wednesday 27 April 2022
|
13:00-13:30
13:30-14:30
|
Hildegard Büning (ESGCT) & Evangelia Yannaki (HSGTRM)
Welcome address
Keynote:
INV01 Toni Cathomen, University of Freiburg
Risk assessment of gene editing associated off-target effects |
14:30-15:10
15:10-15:50 |
Session 1: Spotlight on delivery tools I
INV02 Axel Schambach, Hannover Medical School
What you should know about retro and lentiviral vectors
INV03 Hildegard Büning, Hannover Medical School
AAV - a little virus rocks gene therapy |
| 15:50-16:20 |
Coffee Break |
16:20-17:00
17:00-17:40 |
Session 2: Spotlight on delivery tools II
INV04 Aglaia Athanassiadou, University of Patras
Non-viral gene transfer
INV05 Anne Galy, Genethon
Innate and adaptive immune responses |
17:40-18:20
18:20-19:00 |
Session 3: The payload
INV06 Zoltan Ivics, Paul Elrich Institute, Langen
Wide awake and ready to move: non-viral genome engineering
with Sleeping Beauty transposon vectors
INV07 Alberto Auricchio Tigem, Naples
How to transfer large genes with a small vector? |
| 19:30-22:00 |
Meet the expert dinner at the hotel |
Thursday 28 April 2022
|
09:00-10:00
|
Keynote:
INV08 Juan Bueren, CIEMAT/Ciberer, Madrid
Moving from basic stem cell research to clinical gene therapy? |
10:00-10:40
10:40-11:20 |
Session 4: Gene therapy for primary immuno-deficiencies
INV09 Claire Booth, UCLondon
Evolution of gene therapy for PID and wheredo we go next?
INV10 Giuliana Ferrari, SR Tiget, Milan
The engineering of hematopoietic stem cells to treat genetic
blood disorders |
| 11:20-11:50 |
Coffee Break |
11:50-12:50 |
Keynote:
INV11 Nathalie Cartier, AskBIo
Gene Therapy for neurodegenerative diseases from genetic to complex
diseases : delivery and targets |
| 12:50-14:00 |
Lunch |
14:00-14:40
14:40-15:20 |
Session 5: Gene Therapy for CNS and neuromuscular disease, part I
INV12 Rebeca Matsas, Hellenic Pasteur Institute, Athens
Modelling brain disease: advancing from animal models to human
iPSCs-based organoids.
INV13 Françoise Piguet, ICM Paris
Gene therapy strategy for CNS |
| 15:20-15:50 |
Coffee break |
15:50-16:30
16:30-17:10 |
Session 6: Gene Therapy for CNS and neuromuscular disease, part II
INV14 Stylianos Michalakis, LMU Munich
Can next-generation technologies help overcome existing hurdles in retinal gene therapy?
INV15 Caroline Le Guiner, University of Nantes
Gene therapy for muscle diseases: Focus on rAAV products for
the treatment of Duchenne Muscular Dystrophy |
| 17:10-17:40 |
Coffee break |
17:40-18:20
18:20-19:00 |
Session 7: Immunotherapy and cancer
INV16 Vincenzo Cerullo, University of Helsinki
Dressing viruses in tumor’s clothing: welcome to the cloning-free
oncolytic vaccine era
INV17 HInrich Abken, University of Regensburg
Next generation CARs – the Driver licence to fight cancer |
| 20:00-22:30 |
Dinner at Restaurant |
Friday 29 April 2029
|
09:30-10:30 |
Keynote:
INV18 Evangelia Yannaki, Gene and Cell Therapy Center, Thessaloniki
T cell immunotherapy against leukemia and viruses, including SARS-CoV2 |
| 10:30-11:00 |
Coffee Break |
11:00-11:40
11:40-12:20 |
Session 8: Liver-directed gene therapy
INV19 Giuseppe Ronzitti, Genethon, Paris
Liver gene transfer for the systemic delivery of therapeutic proteins
INV20 Gloria Gonzalez Aseguinolaza, FIMA, Pamplona
Targeting the second largest organ in the human body to fix
inherited diseases |
| 12:20-13:30 |
Lunch |
13:30-14:10
14:10-15:10 |
Session 9: Gene Therapy for lysosomal storage disease
INV21 Francesca Tucci, SR TIget, Milan
Clinical application of gene therapy in lysosomal storage diseases
Keynote:
INV22 Fatima Bosch, UAB, Barcelona
Gene therapy approaches for Mucopolysaccharidosis. |
| 15:10-15:30 |
Closing: Hildegard Büning and Evangelia Yannaki
|